The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Abstract
Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen action by binding to the ER in breast cancers. Tamoxifen has been used ubiquitously in clinical practice during the last 30 years for the treatment of breast cancer and is currently available to reduce the risk of breast cancer in high-risk women. Raloxifene maintains bone density (estrogen-like effect) in postmenopausal osteoporotic women, but at the same time reduces the incidence of breast cancer in both high- and low-risk (osteoporotic) postmenopausal women. Unlike tamoxifen, raloxifene does not increase the incidence of endometrial cancer. Clearly, the simple ER model of estrogen action can no longer be used to explain SERM action at different sites around the body. Instead, a new model has evolved on the basis of the discovery of protein partners that modulate estrogen action at distinct target sites. Coactivators are the principal players that assemble a complex of functional proteins around the ligand ER complex to initiate transcription of a target gene at its promoter site. A promiscuous SERM ER complex creates a stimulatory signal in growth factor receptor–rich breast or endometrial cancer cells. These events cause drug-resistant, SERM-stimulated growth. The sometimes surprising pharmacology of SERMs has resulted in a growing interest in the development of new selective medicines for other members of the nuclear receptor superfamily. This will allow the precise treatment of diseases that was previously considered impossible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932
Self-citationShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily
Oñate, S. A., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (1995) · Science · doi:10.1126/science.270.5240.1354 · Cited by 2,387
Self-citationThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Self-citationCoombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,657
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463 · cited 2×
“dependent transcription factors that have two main purposes: (1) to locate target genes by binding at specific DNA sequences (termed hormone response elements [HREs]) that are located at these genes; and then, (2) to recruit transcriptional coregulators to the gene.(16) Ligands can induce both activation and repressio…”
Self-citationFisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Self-citationStearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Self-citationCummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
The value of estrogen and progesterone receptors in the treatment of breast cancer
Osborne, C. K., Yochmowitz, M. G., Knight, W. A., & McGuire, W. L. (1980) · Cancer · doi:10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u · Cited by 720
Martino, S., Cauley, J. A., Barrett-Connor, E., Powles, T. J., Mershon, J., Disch, D., Secrest, R. J., Cummings, S. R., & For the CORE Investigators (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh319 · Cited by 684
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer
Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1829 · Cited by 670
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M., Come, S., Gertler, S. Z., May, J. T., Burton, G., Dimery, I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 642
Allosteric effects of DNA on transcriptional regulators
Lefstin, J. A., & Yamamoto, K. R. (1998) · Nature · doi:10.1038/31860 · Cited by 488
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Arpino, G., Weiss, H., Lee, A. V., Schiff, R., De Placido, S., Osborne, C. K., & Elledge, R. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji249 · Cited by 484
A NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATS
HARPER, M. J. K., & WALPOLE, A. L. (1967) · Reproduction · doi:10.1530/jrf.0.0130101 · Cited by 445
Boccardo, F., Rubagotti, A., Puntoni, M., Guglielmini, P., Amoroso, D., Fini, A., Paladini, G., Mesiti, M., Romeo, D., Rinaldini, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.120 · Cited by 445
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis, M. M., Robinson, S. P., SATYASWAROOP, P. G., & Jordan, V. C. (1988) · PubMed · Cited by 422
Self-citationDevelopment of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
Lerner, L. J., & Jordan, V. C. (1990) · PubMed · Cited by 417
Self-citation(1988) · PubMed · Cited by 416
Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., & Berthois, Y. (1987) · PubMed · Cited by 403
Gottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 378
Self-citationVegeto, E., Allan, G. F., Schrader, W. T., Tsai, M.-J., McDonnell, D. P., & O'Malley, B. W. (1992) · Cell · doi:10.1016/0092-8674(92)90234-4 · Cited by 377
Self-citationOsborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361
Allan, G. F., Leng, X., Tsai, S. Y., Weigel, N. L., Edwards, D. P., Tsai, M. J., & O'Malley, B. W. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41805-4 · Cited by 355
Self-citationEffects of anti-estrogens on bone in castrated and intact female rats
Jordan, V. C., Phelps, E., & Lindgren, J. U. (1987) · Breast Cancer Research and Treatment · doi:10.1007/bf01806132 · Cited by 324
Self-citationThe Expanding Cosmos of Nuclear Receptor Coactivators
Lonard, D. M., & O'Malley, B. W. (2006) · Cell · doi:10.1016/j.cell.2006.04.021 · Cited by 317
Self-citationSelective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 315
Self-citationGPR30: A G protein-coupled receptor for estrogen
Prossnitz, E. R., Arterburn, J. B., & Sklar, L. A. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.12.010 · Cited by 310
Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi002 · Cited by 310
Influence of Synthetic Oestrogens on Advanced Malignant Disease
Haddow, A., Watkinson, J., Paterson, E., & KOLLER, P. C. (1944) · BMJ · doi:10.1136/bmj.2.4368.393 · Cited by 299
Jordan, V. C., & Brodie, A. M. H. (2007) · Steroids · doi:10.1016/j.steroids.2006.10.009 · Cited by 296
Self-citationSong, R. X.-D., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J., & Santen, R. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1714 · Cited by 293
Schupp, M., Clemenz, M., Gineste, R., Witt, H., Janke, J., Helleboid, S., Hennuyer, N., Ruiz, P., Unger, T., Staels, B., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3442 · Cited by 274
Li, X., Lonard, D. M., Jung, S. Y., Malovannaya, A., Feng, Q., Qin, J., Tsai, S. Y., Tsai, M.-J., & O'Malley, B. W. (2006) · Cell · doi:10.1016/j.cell.2005.11.037 · Cited by 273
Self-citationDowsett, M., Cuzick, J., Wale, C., Howell, T., Houghton, J., & Baum, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4829 · Cited by 260
Lewis, J. S., Meeke, K., Osipo, C., Ross, E. A., Kidawi, N., Li, T., Bell, E., Chandel, N. S., & Jordan, V. C. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji400 · Cited by 244
Self-citationCui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., & Lee, A. V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0318 · Cited by 233
Weihua, Z., Andersson, S., Cheng, G., Simpson, E. R., Warner, M., & Gustafsson, J.-Å. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00436-8 · Cited by 220
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)
Gao, W., & Dalton, J. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.003 · Cited by 215
Jordan, V. C., & Allen (née Naylor), K. E. (1980) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(80)90156-5 · Cited by 214
Self-citationZhou, D. J., Pompon, D., & Chen, S. A. (1990) · PubMed · Cited by 211
JORDAN, V (2007) · Steroids · doi:10.1016/j.steroids.2007.07.009 · Cited by 177
Self-citationSelective estrogen receptor modulation: a personal perspective.
Jordan, V. C. (2001) · PubMed · Cited by 174
Self-citationDowsett, M., Harper-Wynne, C. L., Boeddinghaus, I., Salter, J., Hills, M., Dixon, M., Ebbs, S. R., Gui, G. P., Sacks, N., & Smith, I. E. (2001) · PubMed · Cited by 172
DAVIES, C. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(04)00121-5 · Cited by 170
Shim, W.-S., Conaway, M., Masamura, S., Yue, W., Wang, J.-P., Kumar, R., & Santen, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.1.7270 · Cited by 169
Apoptotic Action of 17 -Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo
Liu, H., Lee, E.-S., Gajdos, C., Pearce, S. T., Chen, B., Osipo, C., Loweth, J., McKian, K., Reyes, A. D. L., Wing, L., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg080 · Cited by 161
Self-citationProspects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs)
Sporn, M. B., Suh, N., & Mangelsdorf, D. J. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02100-1 · Cited by 159
Wolf, D. M., & Jordan, V. C. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689683 · Cited by 155
Self-citationPharmacology of tamoxifen in laboratory animals.
Jordan, V. C., Allen, K. E., & DIX, C. J. (1981) · PubMed · Cited by 142
Self-citationJelovac, D., Sabnis, G. J., Long, B. J., Macedo, L. F., Goloubeva, O. G., & Brodie, A. M. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4502 · Cited by 141
Long, B. J., Jelovac, D., Handratta, V. D., Thiantanawat, A., Macpherson, N. A., Ragaz, J., Goloubeva, O. G., & Brodie, A. M. H. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh076 · Cited by 141
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4482 · Cited by 140
Lieberman, M. E., Gorski, J., & Jordan, V. C. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32484-0 · Cited by 132
Self-citationOsipo, C., Gajdos, C., Liu, H., Chen, B., & Jordan, V. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg079 · Cited by 131
Self-citationGottardis, M. M., Ricchio, M. E., SATYASWAROOP, P. G., et al. (1990) · PubMed · Cited by 128
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal
Lewis, J. S., Osipo, C., Meeke, K., & Jordan, V. C. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.032 · Cited by 128
Self-citationJelovac, D., Macedo, L. F., Goloubeva, O. G., Handratta, V. D., & Brodie, A. M. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2782 · Cited by 123
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture
Welshons, W. V., & Jordan, V. C. (1987) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(87)90062-9 · Cited by 122
Self-citationSabnis, G. J., Jelovac, D., Long, B. J., & Brodie, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4092 · Cited by 111
Kym, P. R., Kort, M. E., Coghlan, M. J., Moore, J. L., Tang, R., Ratajczyk, J. D., Larson, D. P., Elmore, S. W., Pratt, J. K., Stashko, M. A., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020335m · Cited by 109
Murphy, C. S., Langan-Fahey, S. M., McCague, R., & Jordan, V. C. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09527-6 · Cited by 88
Self-citationPeroxisome proliferator-activated receptor modulators as potential chemopreventive agents.
Kopelovich, L., Fay, J. R., Glazer, R. I., & Crowell, J. A. (2002) · PubMed · Cited by 83
Little Molecules with Big Goals
O’Malley, B. W. (2006) · Science · doi:10.1126/science.1132509 · Cited by 77
Self-citationJordan, V. C. (1988) · Cancer Investigation · doi:10.3109/07357908809082124 · Cited by 75
Self-citationEffects of Raloxifene After Tamoxifen on Breast and Endometrial Tumor Growth in Athymic Mice
O'Regan, R. M., Gajdos, C., Dardes, R. C., Reyes, A. D. L., Park, W., RADEMAKER, A. W., & Jordan, V. C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.274 · Cited by 69
Self-citationCormier, E. M., & Jordan, V. C. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90051-5 · Cited by 67
Self-citationLong, B. J., Jelovac, D., Thiantanawat, A., & Brodie, A. M. H. (2002) · PubMed · Cited by 63
Togashi, M., Borngraeber, S., Sandler, B., Fletterick, R. J., Webb, P., & Baxter, J. D. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.01.004 · Cited by 58
Song, R., Zhang, Z., Mor, G., & Santen, R. J. (2005) · APOPTOSIS · doi:10.1007/s10495-005-1903-2 · Cited by 57
Long-Term Exposure to Tamoxifen Induces Hypersensitivity to Estradiol
Berstein, L. M., Wang, J., Zheng, H., Yue, W., Conaway, M. R., & Santen, R. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0433-03 · Cited by 57
Jordan, V. C., & Lieberman, M. E. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15114-6 · Cited by 52
Self-citationJordan, V. C., Lewis, J. S., Osipo, C., & Cheng, D. (2005) · The Breast · doi:10.1016/j.breast.2005.08.022 · Cited by 44
Self-citationDesign and Synthesis of an Array of Selective Androgen Receptor Modulators
Trump, R. P., Blanc, J.-B. E., Stewart, E. L., Brown, P. J., Caivano, M., Gray, D. W., Hoekstra, W. J., Willson, T. M., Han, B., & Turnbull, P. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc060096e · Cited by 34
Effects of Exemestane and Tamoxifen in a Postmenopausal Breast Cancer Model
Jelovac, D., Macedo, L. F., Handratta, V. D., Long, B. J., Goloubeva, O. G., Ingle, J. N., & Brodie, A. M. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0565 · Cited by 34
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens
Brodie, A., Jelovac, D., & Long, B. J. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00368-6 · Cited by 31
Optimising endocrine approaches for the chemoprevention of breast cancer
Jordan, V. C. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.012 · Cited by 30
Self-citationJordan, V. C., Lewis-Wambi, J. S., Kim, H., Cunliffe, H. E., Ariazi, E. A., Sharma, C. G. N., Shupp, H. A., & Swaby, R. F. (2007) · The Breast · doi:10.1016/j.breast.2007.07.020 · Cited by 25
Self-citationBrodie, A., & Mouridsen, H. T. (2003) · American Journal of Clinical Oncology · doi:10.1097/00000421-200308001-00004 · Cited by 14
Lewis-Wambi, J. S., & Jordan, V. C. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00294-7 · Cited by 7
Self-citation
Cited by
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Molecular mechanism of estrogen–estrogen receptor signaling
Yaşar, P., Ayaz, G., User, S. D., Güpür, G., & Muyan, M. (2017) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12006 · Cited by 482
Metadata
- Authors
- Jordan, V. C., & O'Malley, B. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-12-20
- Volume
- 25
- Issue
- 36
- Pages
- 5815-5824
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2052358607
- Cited by
- 324
- References
- 106
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.